CD274 and non-small cell lung carcinoma: Several ICIs (anti-CTLA-4, anti-PD-1, and anti-PD-L1) are able to restore the antitumor immune response and have been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for therapy in advanced NSCLC and other solid tumors.